Completed PHASE3 INTERVENTIONAL NCT00481702

A Study to Evaluate the Safety and Effectiveness of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-abdominal Infections in Adults (0826-802)

A Prospective, Multicenter, Open-Label, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Ertapenem Versus Ceftriaxone/Metronidazole in the Treatment of Intra-Abdominal Infections in Adults

Sponsor: Merck Sharp & Dohme LLC

Conditions Intra-abdominal Infection

Interventions Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks Comparator: metronidazole / Duration of Treatment: 8 Weeks MK0826, /Duration of Treatment : 8 Weeks

Updated 6 times since 2017 Last updated: Feb 17, 2017 Started: Dec 31, 2001 Primary completion: Jun 30, 2003 Completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Intra-abdominal Infection, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 6 data snapshots since 2001. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.